CHENGDU SHENGNUO BIOTEC CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.13 CNY | +1.82% |
|
-1.45% | -10.89% |
| May. 07 | Sheng Nuo Biotec's Unit Gets Nod to Produce Posaconazole Injection | MT |
| Apr. 22 | ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 1,778 | 3,158 | 2,815 | - | - |
| Enterprise Value (EV) 1 | 1,778 | 3,158 | 2,815 | 2,815 | 2,815 |
| P/E ratio | 20.1 x | 45.5 x | 25.6 x | 19.2 x | 14 x |
| Yield | - | 0.71% | - | - | - |
| Capitalization / Revenue | - | 7.26 x | 4.71 x | 3.59 x | 2.81 x |
| EV / Revenue | - | 7.26 x | 4.71 x | 3.59 x | 2.81 x |
| EV / EBITDA | - | 28.9 x | 16.2 x | 12.9 x | 9.2 x |
| EV / FCF | - | - | -97.1 x | 49.3 x | 23.5 x |
| FCF Yield | - | - | -1.03% | 2.03% | 4.25% |
| Price to Book | - | 3.59 x | 2.91 x | 2.56 x | 2.27 x |
| Nbr of stocks (in thousands) | 112,000 | 112,000 | 112,000 | - | - |
| Reference price 2 | 15.87 | 28.20 | 25.13 | 25.13 | 25.13 |
| Announcement Date | 2/24/23 | 2/24/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 435 | 597 | 783.5 | 1,000 |
| EBITDA 1 | - | 109.3 | 174 | 217.5 | 306 |
| EBIT 1 | - | 81.1 | 131 | 169 | 237 |
| Operating Margin | - | 18.64% | 21.94% | 21.57% | 23.7% |
| Earnings before Tax (EBT) 1 | - | 80.12 | 129 | 168.5 | 235 |
| Net income 1 | 62.97 | 70.34 | 109 | 146.5 | 200 |
| Net margin | - | 16.17% | 18.26% | 18.7% | 20% |
| EPS 2 | 0.7900 | 0.6200 | 0.9800 | 1.310 | 1.790 |
| Free Cash Flow 1 | - | - | -28.99 | 57.11 | 119.6 |
| FCF margin | - | - | -4.86% | 7.29% | 11.96% |
| FCF Conversion (EBITDA) | - | - | - | 26.26% | 39.09% |
| FCF Conversion (Net income) | - | - | - | 38.98% | 59.82% |
| Dividend per Share 2 | - | 0.2000 | - | - | - |
| Announcement Date | 2/24/23 | 2/24/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -29 | 57.1 | 120 |
| ROE (net income / shareholders' equity) | - | 8.25% | 11.3% | 13.4% | 16.1% |
| ROA (Net income/ Total Assets) | - | 5.78% | 7.5% | 9.05% | 11.2% |
| Assets 1 | - | 1,217 | 1,453 | 1,619 | 1,786 |
| Book Value Per Share 2 | - | 7.860 | 8.630 | 9.820 | 11.10 |
| Cash Flow per Share 2 | - | 0.7600 | 0.7500 | 0.7400 | - |
| Capex 1 | - | 278 | 124 | 108 | 105 |
| Capex / Sales | - | 63.82% | 20.77% | 13.72% | 10.5% |
| Announcement Date | 2/24/23 | 2/24/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
25.13
CNY
Average target price
38
CNY
Spread / Average Target
+51.21%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.89% | 389M | |
| +15.91% | 41.97B | |
| +22.40% | 22.34B | |
| +18.48% | 15.25B | |
| +16.12% | 14B | |
| +45.12% | 12.06B | |
| -9.58% | 6.8B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +14.18% | 5.49B |
- Stock Market
- Equities
- 688117 Stock
- Financials ChengDu ShengNuo Biotec Co.,Ltd.
